Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
48.97%
Operating Margin
30.92%
Net Margin
14.27%
Efficiency Metrics
Revenue per Expense Ratio
1.45
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
48.16%
Income Tax Rate
0.00%
EPS
0.4100000000
Balance Sheet Analysis
Current Ratio
0.33
Cash Ratio
0.08
Working Capital
$-112.30M
Debt to Equity
0.46
Debt to Assets
28.25%
Equity Ratio
60.93%
Cash Flow Analysis
Operating Cash Flow Ratio
32.12%
Free Cash Flow Ratio
17.19%
CapEx to Revenue
14.94%
Dividends Paid
$64.30M
Stock Buybacks
$5.40M
Total Shareholder Returns
$69.70M
Cash Position Change
-60.06%
Key Takeaways (2023 FY)
Revenue declined by 9.3709327548807%, indicating potential market challenges
Maintained positive net income growth despite revenue changes
Increased dividend payments by 11.44%
Detailed Growth Metrics
Core Performance
Revenue
-9.37%
Net Income
160.20%
EPS
160.29%
Operating Income
-19.35%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
-3.90%
Operating Cash Flow
97.35%
Free Cash Flow
191.87%
Balance Sheet Health
Assets
-7.89%
Debt
-2.52%
Book Value per Share
-3.90%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
11.44%
Shares Outstanding
0.00%
Long Term Trends
3Y Revenue/Share
-31.86%
5Y Revenue/Share
-68.48%
3Y Dividend/Share
364.02%
5Y Dividend/Share
-60.07%